NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
April 27, 2004 • Volume 1 / Number 17 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Chemoprevention Trial for Men at High Risk for Prostate Cancer

Name of the Trial
Phase III Randomized Study of Selenium as Chemoprevention of Prostate Cancer in Patients with High-Grade Prostatic Intraepithelial Neoplasia (SWOG-S9917). See the protocol summary at

Dr. Jim Marshall Principal Investigators
Dr. Jim Marshall, Southwest Oncology Group; Dr. David Jarrard, Eastern Cooperative Oncology Group; and Dr. William Robert Lee, Cancer and Leukemia Group B.

Why Is This Trial Important?
Prostate cancer is an important source of morbidity and mortality among men in the industrialized world. High-grade prostatic intraepithelial neoplasia (HGPIN), a condition characterized by abnormal and uncontrolled growth of the ductal cells of the prostate, may be a precursor to prostate cancer.

Intake of the dietary supplement selenium is believed to protect against prostate cancer. Researchers are interested in determining whether a daily dose of selenium might prevent prostate cancer from developing among men with HGPIN.

"HGPIN is very likely a premalignant lesion for prostate cancer, so it is important to find a chemopreventive agent that will be effective for this high-risk group," said Dr. Marshall. "Selenium supplementation shows promise, so we need to know if it might prevent HGPIN from developing into prostate cancer."

Who Can Join This Trial?
Researchers seek to enroll 465 patients aged 40 or over with a diagnosis of HGPIN and no evidence of cancer. See the full list of eligibility criteria for this trial at

Where Is This Trial Taking Place?
Study sites in the United States and Puerto Rico are enrolling patients in this trial. See the list of sites at

Who to Contact
See the list of study contacts at or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.

An archive of "Featured Clinical Trial" columns is available at